October 13, 2021, Greenville, N.C. – Metrics Contract Services, the contract pharmaceutical development and manufacturing division of Mayne Pharma, has invested in additional equipment to enhance capacity in early phase drug development. Another Xcelodose® 600S precision powder micro-dosing system will further provide capacity and efficiency improvements in meeting increasing client demand for preclinical and early phase clinical GMP supply.
Metrics’ new Xcelodose® 600S is a strategic addition for Metrics’ formulation development team. The 600S can dispense dose weights as low as 100 micrograms, allowing for precise, accurate and repeated filling of capsules and other small dose containers without excipients or bulking agents. Most formulated products can also be filled without segregation.
“The Xcelodose® 600S will be utilized within its own custom hard-walled isolator, which will mitigate the risk of cross contamination and operator exposure,” said Brad Gold, VP, Pharmaceutical Development.
“Adding another Xcelodose® will enable us to greatly increase our capacity specifically in our early phase/first in human development and manufacturing and will help accelerate our fast-track timelines,” said Gold. “The addition is part of Metrics Contract Services’ commitment to evaluation of capacity utilization and continuous improvement on behalf of our customers. We are continually assessing and investing in solutions to accelerate the manufacturing of our client’s clinical supplies, while ensuring quality at all times.”
Metrics will install the new Xcelodose® 600S in its state-of-the-art facility in Greenville, NC.